Aptevo Therapeutics

Oncology and hematology therapeutics

ALG.APV-527 Clin0 solid tumors; APVO603 Clin0 solid tumors; APVO442 RD/Clin0 prostate cancer; APVO711 RD/Clin0 solid tumors

Aptevo Therapeutics is developing novel therapeutics for oncology and hematology. The immune system, including T cells, play an important role in the detection and killing of tumor cells, but is often suppressed by the tumor itself. Using their proprietary modular protein technology platform, ADAPTIR, Aptevo is designing both mono- and bispecific protein therapeutics to redirect T cells to kill tumor cells. Aptevo’s lead candidate, APVO436, is a bispecific candidate that is designed to redirect CD3-expressing T cells to kill CD123-positive tumors for treatment of acute myeloid leukemia. Apetvo has also built their ADAPTIR-FLEX platform, which expands upon ADAPTIR by enabling the design of protein therapeutics with multivalent binding to improve specificity and potency.